NCT00006016View on ClinicalTrials.gov

Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver Cancer
Interventions
DRUG

thalidomide

Given orally

DRUG

doxorubicin hydrochloride

Given transarterially (chemoembolization)

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

10016

New York University Langone Medical Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00006016 - Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | Biotech Hunter | Biotech Hunter